NVP-AST487 positively combines with Ara-c, doxorubicin, and PKC412. (A) Proliferation study investigating the combination of NVP-AST487 and Ara-c. Results shown here are representative of 2 independent studies. Calcusyn analysis suggests slight to moderate synergism between the 2 agents (ED₂₅: 0.84008; ED₅₀: 0.77655; ED₇₅: 0.73874; ED₉₀: 0.72264). (B) Proliferation study investigating the combination of NVP-AST487 and doxorubicin, performed once. Calcusyn analysis suggests slight synergy between the 2 agents (ED₂₅: 0.88419; ED₅₀: 0.87274; ED₇₅: 0.86262; ED₉₀: 0.85377). (C) Proliferation study investigating the combination of NVP-AST487 and PKC412, performed once. Calcusyn analysis suggests effects that ranged from slight antagonism to slight synergism between the 2 agents (ED₂₅: 0.88582; ED₅₀: 0.95322; ED₇₅: 1.02619; ED₉₀: 1.10522).